KatherineAHighMD
Pediatric Hematology & Oncology • Philadelphia, PAProfessor, Pediatrics, Perelman School of Medicine
Dr. High is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3401 Civic Center Blvd
Children's Hospital Of Philadelphia - Hem/Onc
Philadelphia, PA 19104Phone+1 215-590-3535Fax+1 215-590-3992
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1981 - 1984
University of North Carolina HospitalsResidency, Internal Medicine, 1978 - 1981
University of North Carolina at Chapel Hill School of MedicineClass of 1978
Certifications & Licensure
PA State Medical License 1992 - 2024
NC State Medical License 1981 - 1998- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Elected Member Institute of Medicine, 2007
- Elected Member The American Society for Clinical Investigation, 1991
- Whos Who in Medicine and Healthcare Marquis Whos Who
- Join now to see all
Publications & Presentations
PubMed
- Gene and cell therapy in 2023: Rich pipeline, slimming resources?Katherine A High
Molecular Therapy. 2024-01-03 - 1 citationsTrial by "Firsts": Clinical Trial Design and Regulatory Considerations in the Development and Approval of the First AAV Gene Therapy Product in the United States.Kathleen Z Reape, Katherine A High
Cold Spring Harbor Perspectives in Medicine. 2023-05-02 - 3 citationsPreclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia ALiron Elkouby, Sean M. Armour, Raffaella Toso, Marti A. DiPietro, Robert J. Davidson
Molecular Therapy. Methods & Clinical Development. 2021-11-24
Abstracts/Posters
- Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 YearKatherine A. High, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Hemostasis and Thrombosis Poster Walk for Trainees61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Activity of a FIX-Padua Transgene Product in Commonly Used FIX:C One-Stage and Chromogenic Assay Systems Following PF-06838435 (SPK-9001) Gene Delivery2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Biologic Therapeutics Seminar Series - Systems Approaches to Antibody-based Immunotherapy of CancerWashington University School of Medicine, Saint Louis, Missouri - 5/16/2012
Press Mentions
Moore’s Law for RadiologistsNovember 25th, 2024
Medical Groups Welcome Medicare Stabilization BillNovember 8th, 2024
ACR Advocates for CPT Code ChangesSeptember 26th, 2024- Join now to see all
Grant Support
- Gene Therapy For Hemophilia Using Muscle-Expressed FviiaNational Heart, Lung, And Blood Institute2011
- Administrative Core For Gene Therapy Of HemophiliaNational Heart, Lung, And Blood Institute2011
- Immune Responses To Capsid In Aav-Mediated Gene TransferNational Heart, Lung, And Blood Institute2010–2011
- Pediatric Hematology Research Training ProgramNational Heart, Lung, And Blood Institute2004–2011
- Gene Therapy For HemophiliaNational Heart, Lung, And Blood Institute2004–2011
- Clinical Trials Training SymposiumNational Heart, Lung, And Blood Institute2010
- Pathway To Accelerate Clinical Development In Gene Transfer: CGMP Vector CoreNational Center For Research Resources2010
- Safety &Efficacy Of Intravas. Del. Of Aav-F.Ix To Skeletal MuscleNational Heart, Lung, And Blood Institute2005–2009
- Immune Responses To AAV In Gene Transfer For HemophiliaNational Heart, Lung, And Blood Institute2005–2009
- Biological Roles Of Factors X And XANational Heart, Lung, And Blood Institute2004–2007
- Administrative CoreNational Heart, Lung, And Blood Institute2005
- Core A- Administrative CoreNational Heart, Lung, And Blood Institute2004
- AAV Mediated Muscle Directed Gene Therapy For Hemophilia BNational Heart, Lung, And Blood Institute2004
- Gene Therapy For HemophiliaNational Heart, Lung, And Blood Institute2000–2003
- Pediatric Hematology Research Training ProgramNational Heart, Lung, And Blood Institute1997–2003
- Gene Based Approach To Treating Hemophilic InhibitorsNational Heart, Lung, And Blood Institute2000–2002
- Core--TrainingNational Heart, Lung, And Blood Institute2000–2002
- AAV Mediated Muscle Directed Gene Therapy For Hemophilia BNational Heart, Lung, And Blood Institute2000–2002
- Inhibitor Formation In Gene Therapy For HemophiliaNational Heart, Lung, And Blood Institute1998–2001
- Gene Therapy Of Hemophilia B Using Hematopoietic Stem CellsNational Heart, Lung, And Blood Institute1996–2000
- Molecular Interactions Of Blood Coagulation Factor XANational Heart, Lung, And Blood Institute1996–1999
- Novel Stratagies For Gene Therapy Of Hemophilia BNational Heart, Lung, And Blood Institute1994–1998
- Regulation &Biosynthesis Of Vitamin K-Dependent FactorsNational Heart, Lung, And Blood Institute1992–1995
- Regulation &Biosynthesis Of Vitamin K-Dependent FactorsNational Heart, Lung, And Blood Institute1992
- Factor Ix--Molecular Defects &Regulation Of ExpressionNational Heart, Lung, And Blood Institute1988–1991
- Factor IX: Molecular Defects And Regulation Of ExpressiNational Heart, Lung, And Blood Institute1987
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
